Medpace Holdings, Inc. (MEDP): Net Income
$451.12M
Year ended 2025-12-31
$491.50M
Trailing 12 months to 2026-06-30
+22.5%
3-year compound annual growth
+25.4%
5-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $451.12M | +11.6% | 2026-02-10, From 2025-01-01 |
| 2024-12-31 | $404.39M | +43.0% | 2026-02-10, From 2024-01-01 |
| 2023-12-31 | $282.81M | +15.3% | 2026-02-10, From 2023-01-01 |
| 2022-12-31 | $245.37M | +34.9% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $181.85M | +25.1% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $145.38M | +44.7% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $100.44M | +37.2% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $73.19M | +87.1% | 2021-02-16, From 2018-01-01 |
| 2017-12-31 | $39.12M | +191.4% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $13.43M | n/m | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | -$8.67M | n/a | 2018-02-27, From 2015-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $451.12M | +11.6% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | -$142.16M | n/m |
| Incyte Corp (INCY) | 2025-12-31 | $1.29B | n/m |
| Icon PLC (ICLR) | 2025-12-31 | $229.34M | -69.0% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $1.36B | -0.9% |
| NRC Health (NRC) | 2025-12-31 | $11.60M | -53.2% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | -$44.63M | n/m |
| OmniAb, Inc. (OABI) | 2025-12-31 | -$64.78M | n/m |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | -$12.43M | n/m |
Compare MEDP, CRL, INCY, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗